Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Changes in Age at Diagnosis and Nutritional Course of Celiac Disease in the Last Two Decades.

Villanueva M, Oyarzún A, Leyton B, González M, Navarro E, Canales P, Ossa C, Muñoz MP, Bascuñán KA, Araya M.

Nutrients. 2020 Jan 6;12(1). pii: E156. doi: 10.3390/nu12010156.

2.

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.

Nittoli T, Kelly MP, Delfino F, Rudge J, Kunz A, Markotan T, Spink J, Chen Z, Shan J, Navarro E, Tait M, Provoncha K, Giurleo J, Zhao F, Jiang X, Hylton D, Makonnen S, Hickey C, Kirshner JR, Thurston G, Papadopoulos N.

Bioorg Med Chem. 2018 May 15;26(9):2271-2279. doi: 10.1016/j.bmc.2018.02.025. Epub 2018 Feb 21.

PMID:
29605304
3.

[Transition to adulthood of adolescents with inflammatory bowel disease].

Navarro E, Ossa JC, Simian D, Quera R.

Rev Med Chil. 2015 Jun;143(6):767-73. doi: 10.4067/S0034-98872015000600010. Review. Spanish.

4.

[Non-celiac gluten sensitivity: Another condition that responds to gluten].

Navarro E, Araya M.

Rev Med Chil. 2015 May;143(5):619-26. doi: 10.4067/S0034-98872015000500010. Review. Spanish.

5.

The structural basis for the function of two anti-VEGF receptor 2 antibodies.

Franklin MC, Navarro EC, Wang Y, Patel S, Singh P, Zhang Y, Persaud K, Bari A, Griffith H, Shen L, Balderes P, Kussie P.

Structure. 2011 Aug 10;19(8):1097-107. doi: 10.1016/j.str.2011.01.019.

6.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

7.

Development of heparanase inhibitors for anti-cancer therapy.

Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z.

Curr Med Chem. 2006;13(18):2101-11. Review.

PMID:
16918340
8.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Miao HQ, Hu K, Jimenez X, Navarro E, Zhang H, Lu D, Ludwig DL, Balderes P, Zhu Z.

Biochem Biophys Res Commun. 2006 Jun 23;345(1):438-45. Epub 2006 May 2.

PMID:
16682007
9.

1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.

Pan W, Miao HQ, Xu YJ, Navarro EC, Tonra JR, Corcoran E, Lahiji A, Kussie P, Kiselyov AS, Wong WC, Liu H.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):409-12. Epub 2005 Oct 21.

PMID:
16246560
10.

N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.

Xu YJ, Miao HQ, Pan W, Navarro EC, Tonra JR, Mitelman S, Camara MM, Deevi DS, Kiselyov AS, Kussie P, Wong WC, Liu H.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):404-8. Epub 2005 Oct 21.

PMID:
16246551
11.

High heparanase activity in multiple myeloma is associated with elevated microvessel density.

Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD.

Cancer Res. 2003 Dec 15;63(24):8749-56.

12.

Cloning, expression, and purification of mouse heparanase.

Miao HQ, Navarro E, Patel S, Sargent D, Koo H, Wan H, Plata A, Zhou Q, Ludwig D, Bohlen P, Kussie P.

Protein Expr Purif. 2002 Dec;26(3):425-31.

PMID:
12460766

Supplemental Content

Loading ...
Support Center